Safety, Clinical Tolerability and Immunogenicity of gpASIT+TM Administered Subcutaneously to Hay Fever Patients Either Alone or in Presence of DnaK Immunoregulating Adjuvant.

Trial Profile

Safety, Clinical Tolerability and Immunogenicity of gpASIT+TM Administered Subcutaneously to Hay Fever Patients Either Alone or in Presence of DnaK Immunoregulating Adjuvant.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Grass pollen allergy immunotherapy-BioTech Tools (Primary) ; DnaK
  • Indications Allergic rhinitis; Grass pollen hypersensitivity
  • Focus Adverse reactions
  • Sponsors BioTech Tools
  • Most Recent Events

    • 23 May 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 01 Aug 2012 Planned End Date changed from 1 Jun 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 01 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top